What do we have and what do we need?
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Q&A: Early research findings and clinical experiences with a new multifocal IOL
Frank Kerkhoff, MD, shares his experiences with the Johnson & Johnson Tecnis Odyssey lens
New microbial strain produces high yields of lutein for AMD, cataract prevention
Researchers at the Korea Advanced Institute of Science and Technology demonstrated the next-generation strategy for sustainable synthesis
Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients
Alcon's Clareon Panoptix Pro IOL enhances cataract surgery with advanced light utilization and low visual disturbance.
Clareon Panoptix Pro IOL (Alcon) approved in Canada
The trifocal IOL is designed to deliver lower light scatter and higher-reported light utilisation
Nationwide free transport for cataract patients through SpaMedica
SpaMedica to offer free transport for all NHS cataract patients, supporting community care and reducing health inequalities.
How a newly defined category of IOLs can benefit patient outcomes
A new functional classification can help achieve precise vision goals